This research project will explore negative symptoms of schizophrenia, such as motivational deficits, by examining the relationship between inflammation and reward-related brain regions. To accomplish this, we will administer a single infusion of either the anti-inflammatory medication infliximab or placebo (n=10 per group) to patients with high inflammation. This study is important because schizophrenia can be a chronic and debilitating neuropsychiatric disorder and negative symptoms are some of the most difficult aspects of schizophrenia associated with worst functional outcomes. These symptoms do not typically respond to antipsychotic therapies, and as such, there are no current medications to treat negative symptoms.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Changes in Monetary Incentive Delay Task (MID)
Timeframe: Study visits: 1-3 days before intervention and 6 weeks post-intervention
Changes in Effort Based Decision Making Task (EBDM)
Timeframe: Study Visits :1-3 days before intervention,3 days post intervention, 1 week and 2 weeks post-intervention
Changes in C-Reactive Protein (CRP)
Timeframe: Study Visits :1-3 days before intervention, immediately after the intervention, 1 day post-intervention, 3 days, 1 week and 2 weeks post-intervention
Changes in Brief Negative Symptom Scale (BNSS)
Timeframe: Study Visits :1-3 days before intervention,3 days post intervention, 1 week and 2 weeks post-intervention